|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SAA1 |
Gene summary for SAA1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SAA1 | Gene ID | 6288 |
| Gene name | serum amyloid A1 | |
| Gene Alias | PIG4 | |
| Cytomap | 11p15.1 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | P0DJI8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6288 | SAA1 | GSM4909281 | Human | Breast | IDC | 6.54e-16 | -8.21e-01 | 0.21 |
| 6288 | SAA1 | GSM4909282 | Human | Breast | IDC | 9.61e-16 | 1.93e-01 | -0.0288 |
| 6288 | SAA1 | GSM4909285 | Human | Breast | IDC | 1.20e-35 | -1.13e+00 | 0.21 |
| 6288 | SAA1 | GSM4909286 | Human | Breast | IDC | 1.75e-49 | -1.23e+00 | 0.1081 |
| 6288 | SAA1 | GSM4909287 | Human | Breast | IDC | 3.75e-03 | -4.08e-01 | 0.2057 |
| 6288 | SAA1 | GSM4909289 | Human | Breast | IDC | 7.30e-03 | -8.25e-01 | 0.1064 |
| 6288 | SAA1 | GSM4909290 | Human | Breast | IDC | 1.04e-33 | -1.19e+00 | 0.2096 |
| 6288 | SAA1 | GSM4909291 | Human | Breast | IDC | 2.53e-34 | -1.23e+00 | 0.1753 |
| 6288 | SAA1 | GSM4909292 | Human | Breast | IDC | 5.11e-08 | -1.23e+00 | 0.1236 |
| 6288 | SAA1 | GSM4909293 | Human | Breast | IDC | 1.32e-24 | -9.02e-01 | 0.1581 |
| 6288 | SAA1 | GSM4909294 | Human | Breast | IDC | 8.00e-36 | -1.04e+00 | 0.2022 |
| 6288 | SAA1 | GSM4909296 | Human | Breast | IDC | 3.97e-24 | -9.89e-01 | 0.1524 |
| 6288 | SAA1 | GSM4909297 | Human | Breast | IDC | 1.28e-36 | -1.06e+00 | 0.1517 |
| 6288 | SAA1 | GSM4909298 | Human | Breast | IDC | 9.72e-32 | -1.08e+00 | 0.1551 |
| 6288 | SAA1 | GSM4909300 | Human | Breast | IDC | 1.29e-07 | 7.13e-01 | 0.0334 |
| 6288 | SAA1 | GSM4909301 | Human | Breast | IDC | 5.62e-49 | -1.21e+00 | 0.1577 |
| 6288 | SAA1 | GSM4909302 | Human | Breast | IDC | 3.69e-42 | -1.16e+00 | 0.1545 |
| 6288 | SAA1 | GSM4909303 | Human | Breast | IDC | 4.38e-07 | -9.10e-01 | 0.0438 |
| 6288 | SAA1 | GSM4909304 | Human | Breast | IDC | 7.54e-50 | -1.22e+00 | 0.1636 |
| 6288 | SAA1 | GSM4909305 | Human | Breast | IDC | 3.17e-04 | -5.14e-01 | 0.0436 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003559215 | Prostate | Tumor | establishment of protein localization to extracellular region | 87/3246 | 360/18723 | 5.65e-04 | 4.10e-03 | 87 |
| GO:005070814 | Prostate | Tumor | regulation of protein secretion | 66/3246 | 268/18723 | 1.49e-03 | 9.19e-03 | 66 |
| GO:000759614 | Prostate | Tumor | blood coagulation | 53/3246 | 217/18723 | 4.89e-03 | 2.39e-02 | 53 |
| GO:005081714 | Prostate | Tumor | coagulation | 54/3246 | 222/18723 | 4.95e-03 | 2.42e-02 | 54 |
| GO:000759914 | Prostate | Tumor | hemostasis | 53/3246 | 222/18723 | 7.87e-03 | 3.50e-02 | 53 |
| GO:004206028 | Skin | AK | wound healing | 91/1910 | 422/18723 | 2.93e-12 | 6.67e-10 | 91 |
| GO:004578528 | Skin | AK | positive regulation of cell adhesion | 85/1910 | 437/18723 | 3.40e-09 | 2.79e-07 | 85 |
| GO:005090015 | Skin | AK | leukocyte migration | 63/1910 | 369/18723 | 3.00e-05 | 5.15e-04 | 63 |
| GO:006032610 | Skin | AK | cell chemotaxis | 53/1910 | 310/18723 | 1.20e-04 | 1.50e-03 | 53 |
| GO:003059510 | Skin | AK | leukocyte chemotaxis | 42/1910 | 230/18723 | 1.36e-04 | 1.68e-03 | 42 |
| GO:007162114 | Skin | AK | granulocyte chemotaxis | 26/1910 | 125/18723 | 3.17e-04 | 3.24e-03 | 26 |
| GO:009752915 | Skin | AK | myeloid leukocyte migration | 39/1910 | 220/18723 | 4.30e-04 | 4.05e-03 | 39 |
| GO:00716748 | Skin | AK | mononuclear cell migration | 35/1910 | 196/18723 | 7.20e-04 | 6.10e-03 | 35 |
| GO:005087820 | Skin | AK | regulation of body fluid levels | 58/1910 | 379/18723 | 1.11e-03 | 8.61e-03 | 58 |
| GO:003059313 | Skin | AK | neutrophil chemotaxis | 21/1910 | 103/18723 | 1.50e-03 | 1.08e-02 | 21 |
| GO:000759910 | Skin | AK | hemostasis | 37/1910 | 222/18723 | 1.89e-03 | 1.29e-02 | 37 |
| GO:009753010 | Skin | AK | granulocyte migration | 27/1910 | 148/18723 | 2.01e-03 | 1.35e-02 | 27 |
| GO:000759610 | Skin | AK | blood coagulation | 36/1910 | 217/18723 | 2.34e-03 | 1.54e-02 | 36 |
| GO:000181917 | Skin | AK | positive regulation of cytokine production | 67/1910 | 467/18723 | 2.59e-03 | 1.67e-02 | 67 |
| GO:00321024 | Skin | AK | negative regulation of response to external stimulus | 61/1910 | 420/18723 | 2.96e-03 | 1.87e-02 | 61 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| SAA1 | FPR2 | SAA1_FPR2 | SAA | Cervix | ADJ |
| SAA1 | FPR2 | SAA1_FPR2 | SAA | Cervix | CC |
| SAA1 | FPR2 | SAA1_FPR2 | SAA | Cervix | Healthy |
| SAA1 | FPR2 | SAA1_FPR2 | SAA | Cervix | Precancer |
| SAA1 | FPR2 | SAA1_FPR2 | SAA | HNSCC | ADJ |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SAA1 | SNV | Missense_Mutation | rs139332456 | c.79N>A | p.Glu27Lys | p.E27K | P0DJI8 | protein_coding | deleterious(0) | possibly_damaging(0.746) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SAA1 | SNV | Missense_Mutation | c.239G>C | p.Arg80Thr | p.R80T | P0DJI8 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SAA1 | SNV | Missense_Mutation | c.169N>T | p.Arg57Trp | p.R57W | P0DJI8 | protein_coding | tolerated(0.06) | possibly_damaging(0.458) | TCGA-JX-A3Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SAA1 | SNV | Missense_Mutation | c.258N>A | p.Phe86Leu | p.F86L | P0DJI8 | protein_coding | tolerated(0.85) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| SAA1 | SNV | Missense_Mutation | c.258N>A | p.Phe86Leu | p.F86L | P0DJI8 | protein_coding | tolerated(0.85) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| SAA1 | SNV | Missense_Mutation | c.38N>C | p.Val13Ala | p.V13A | P0DJI8 | protein_coding | tolerated(0.06) | benign(0.043) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SAA1 | SNV | Missense_Mutation | novel | c.160N>G | p.Phe54Val | p.F54V | P0DJI8 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SAA1 | SNV | Missense_Mutation | rs559587106 | c.272N>T | p.Ala91Val | p.A91V | P0DJI8 | protein_coding | tolerated(0.51) | benign(0.006) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SAA1 | SNV | Missense_Mutation | c.63N>A | p.Phe21Leu | p.F21L | P0DJI8 | protein_coding | tolerated(0.09) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SAA1 | SNV | Missense_Mutation | c.360G>T | p.Glu120Asp | p.E120D | P0DJI8 | protein_coding | tolerated(1) | benign(0) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6288 | SAA1 | DRUGGABLE GENOME | IL-1RA | ANAKINRA | 1717568 | |
| 6288 | SAA1 | DRUGGABLE GENOME | NAPROXEN | NAPROXEN | 1729367 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |